HLA-A^＊0201限制性AFP抗原决定簇肽特异性肝癌疫苗的制备  

Preparing for tumor vaccines of human HLA-A^＊0201-restricted AFP epitope peptides

作　　者：刘扬[1] 陆崇德 吴孟超[2] Lisa H.Butterfield 

机构地区：[1]同济大学附属第十人民医院肝胆外科,上海200072 [2]上海东方肝胆外科医院肿瘤综合治疗科,上海200438 [3]美国匹兹堡大学肿瘤研究所,外科学和免疫学组

出　　处：《同济大学学报（医学版）》2009年第6期30-33,共4页Journal of Tongji University(Medical Science)

基　　金：上海市"浦江人才计划"资助项目(07PJ14004)

摘　　要：目的探讨人HLA-A*0201限制性AFP抗原决定簇肽(含MHC-Ⅰ类分子HLA-A*0201)作为原发性肝癌特异性抗原制备肝癌肿瘤疫苗的可行性。方法应用14個AFP抗原决定簇肽片段分別体外脉冲刺激健康人血液树突状細胞(DC),將DC与自体T淋巴细胞共同培养并扩增其数量,使AFP抗原决定簇肽导入CD8+阳性T淋巴细胞(CD8+-CTL)并对表达相应AFP抗原决定簇肽的K562/A 2.1细胞(人慢性髓原性白血病细胞株K562转染人HLA-A*0201基因)产生特异性杀伤并释放gamm a-干扰素(ELISPOT测定)。结果有4个AFP抗原决定簇肽对表达相应AFP抗原决定簇肽的K562/A 2.1细胞杀伤能力较?,称之为免疫决定簇肽(Immunodom inant);另有10个AFP抗原决定簇肽对表达相应AFP抗原决定簇肽的K562/A 2.1细胞杀伤能力較弱,称之为亚免疫决定簇肽(Subdom inant)。结论AFP抗原决定簇肽可以作为肝癌特异性抗原制备肝癌肿瘤疫苗,K562/A 2.1细胞可以作为有效的抗原提呈细胞(APC)用于实验研究。Objective To study the possibility of using HLA-A^＊0201-restricted peptides from human AFP as specific antigen of primary liver cancer for tumor vaccines development. Methods Drentritic cells （DC） were respectively pulsed with 14 restricted peptides, mixed with T lymphocytes for proliferation in cocultivation, followed by transduction of AFP peptides into CD8-positive T cells （ CD8^＋ -CTL） which can kill K562/A 2.1 cells expressing HLA-A^＊0201-restricted peptides of AFP and release gamma-IFN （ ELISPOT assay）. Results Four HLA-A^＊0201-restricted peptides of AFP were more potent in killing K562/A 2. 1 cells, hence were named as Immunodominants; while other 10 AFP peptides with less potency were called Immuno-Subdominants. Conclusion HLA-A^＊0201-restricted peptides of AFP may function as specific antigen to prepare liver tumor vaccines, and K562/A 2.1 can be effective antigen presentation cells （APC） in experimental research.

关 键 词：肿瘤 肝细胞 肝癌疫苗 甲胎蛋白类 

分 类 号：R575[医药卫生—消化系统]